Introduction: Deep surgical site infections (DSSI) usually require secondary treatments. The aim of this study was to compare the total length of hospitalisation (LOH), intensive care unit (ICU) duration, and total treatment costs in patients with DSSI versus without DSSI after open radical cystectomy (ORC) and urinary diversion. Material and Methods: Prospective case-control study in a tertiary care hospital in patients after ORC with urinary diversion during April 2008 to July 2012. DSSI was defined based on Centers for Disease Control and Prevention criteria. Matched-pair analysis for patients with versus without DSSI was done in 1:2 ratios. Patients with superficial surgical site infections (SSI) were excluded from analysis. Results: In total, 189 operations were performed. Thirty-eight patients (20.1%) developed SSI of which 28 patients (14.8%) had DSSI. Out of 28 patients, 27 (96.4%) were with DSSI and required surgical re-intervention. Due to insufficient matching criteria, 11 patients with DSSI were excluded from analyses. Consequently, 17 patients with DSSI were matched with 34 patients without DSSI. Significant differences were seen for median overall LOH (30 vs. 18 days, p < 0.001), median ICU duration (p = 0.024), and median overall treatment costs (€17,030 vs. €11,402, p = 0.011). Conclusions: DSSI significantly increases LOH (67%) and treatment costs (49%), adding up to a financial loss for the hospital of approximately €5,500 in patients with DSSI.

Keywords:
Cystectomy, Postoperative wound infections, Deep surgical site infection, Length of stay, Health insurance reimbursement, Treatment costs
1.
Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA; European Association of Urology (EAU): Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59:1009-1018.
3.
Konety BR, Allareddy V, Herr H: Complications after radical cystectomy: analysis of population-based data. Urology 2006;68:58-64.
4.
Berger I, Martini T, Wehrberger C, Comploj E, Ponholzer A, Wolfgang M, Breinl E, Dunzinger M, Hofbauer J, Höltl W, Jeschke K, Krause S, Kugler W, Pauer W, Rauchenwald M, Pycha A, Madersbacher S: Perioperative complications and 90-day mortality of radical cystectomy in the elderly (75+): a retrospective, multicentre study. Urol Int 2014;93:296-302.
5.
Comploj E, West J, Mian M, Kluth LA, Karl A, Dechet C, Shariat SF, Stief CG, Trenti E, Palermo S, Lodde M, Horninger W, Madersbacher S, Pycha A: Comparison of complications from radical cystectomy between old-old versus oldest-old patients. Urol Int 2015;94:25-30.
6.
Roghmann F, Sukumar S, Ravi P, Trinh VQ, Meskawi M, Ghani KR, Sammon JD, Friedman AA, Peabody JO, Menon M, Noldus J, Karakiewicz PI, Sun M, Trinh QD: Radical cystectomy in the elderly: national trends and disparities in perioperative outcomes and quality of care. Urol Int 2014;92:27-32.
7.
Schiffmann J, Gandaglia G, Larcher A, Sun M, Tian Z, Shariat SF, McCormack M, Valiquette L, Montorsi F, Graefen M, Saad F, Karakiewicz PI: Contemporary 90-day mortality rates after radical cystectomy in the elderly. Eur J Surg Oncol 2014;40:1738-1745.
8.
Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, Raj G, Bochner BH, Dalbagni G, Herr HW, Donat SM: Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009;55:164-174.
9.
Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-675.
10.
Hara N, Kitamura Y, Saito T, Komatsubara S, Nishiyama T, Takahashi K: Perioperative antibiotics in radical cystectomy with ileal conduit urinary diversion: efficacy and risk of antimicrobial prophylaxis on the operation day alone. Int J Urol 2008;15:511-515.
11.
Kyoda Y, Takahashi S, Takeyama K, Masumori N, Tsukamoto T: Decrease in incidence of surgical site infections in contemporary series of patients with radical cystectomy. J Infect Chemother 2010;16:118-122.
12.
Takeyama K, Matsukawa M, Kunishima Y, Takahashi S, Hotta H, Nishiyama N, Tsukamoto T: Incidence of and risk factors for surgical site infection in patients with radical cystectomy with urinary diversion. J Infect Chemother 2005;11:177-181.
13.
Takada N, Abe T, Shinohara N, Sazawa A, Maruyama S, Shinno Y, Sato S, Mitsuhashi K, Sato T, Sugishita K, Kamota S, Yamashita T, Ishizaki J, Hioka T, Mouri G, Ono T, Miyajima N, Sakuta T, Mochizuki T, Aoyagi T, Katano H, Akino T, Hirakawa K, Minami K, Kumagai A, Seki T, Togashi M, Nonomura K: Peri-operative morbidity and mortality related to radical cystectomy: a multi-institutional retrospective study in Japan. BJU Int 2012;110(11 pt B):E756-E764.
14.
Abe T, Takada N, Shinohara N, Matsumoto R, Murai S, Sazawa A, Maruyama S, Tsuchiya K, Kanzaki S, Nonomura K: Comparison of 90-day complications between ileal conduit and neobladder reconstruction after radical cystectomy: a retrospective multi-institutional study in Japan. Int J Urol 2014;21:554-559.
15.
Gondo T, Ohno Y, Nakashima J, Hashimoto T, Takizawa I, Tanaka A, Shimodaira K, Satake N, Takeuchi H, Nakagami Y, Ohori M, Tachibana M: Factors predicting incisional surgical site infection in patients undergoing open radical cystectomy for bladder cancer. Int J Clin Oncol 2014;19:935-939.
16.
Konety BR, Allareddy V: Influence of post-cystectomy complications on cost and subsequent outcome. J Urol 2007;177:280-287; discussion 287.
17.
Hautmann RE, de Petriconi RC, Volkmer BG: Lessons learned from 1,000 neobladders: the 90-day complication rate. J Urol 2010;184:990-994.
18.
Lavallée LT, Schramm D, Witiuk K, Mallick R, Fergusson D, Morash C, Cagiannos I, Breau RH: Peri-operative morbidity associated with radical cystectomy in a multicenter database of community and academic hospitals. PLoS One 2014;9:e111281.
19.
Gili-Ortiz E, González-Guerrero R, Béjar-Prado L, López-Méndez J, Ramírez-Ramírez G: Surgical site infections in patients who undergo radical cystectomy: excess mortality, stay prolongation and hospital cost overruns. Actas Urol Esp 2015;39:210-216.
20.
Davies BJ, Allareddy V, Konety BR: Effect of postcystectomy infectious complications on cost, length of stay, and mortality. Urology 2009;73:598-602.
21.
Horan TC, Andrus M, Dudeck MA: CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008;36:309-332.
22.
Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR: Guideline for prevention of surgical site infection, 1999. Centers for disease control and prevention (CDC) hospital infection control practices advisory committee. Am J Infect Control 1999;27:97-132.
23.
Braxton JH, Marrin CA, McGrath PD, Morton JR, Norotsky M, Charlesworth DC, Lahey SJ, Clough R, Ross CS, Olmstead EM, O'Connor GT: 10-year follow-up of patients with and without mediastinitis. Semin Thorac Cardiovasc Surg 2004;16:70-76.
24.
Ridderstolpe L, Gill H, Borga M, Rutberg H, Ahlfeldt H: Canonical correlation analysis of risk factors and clinical outcomes in cardiac surgery. J Med Syst 2005;29:357-377.
25.
Ridderstolpe L, Gill H, Granfeldt H, Ahlfeldt H, Rutberg H: Superficial and deep sternal wound complications: incidence, risk factors and mortality. Eur J Cardiothorac Surg 2001;20:1168-1175.
26.
Graf K, Ott E, Vonberg RP, Kuehn C, Haverich A, Chaberny IF: Economic aspects of deep sternal wound infections. Eur J Cardiothorac Surg 2010;37:893-896.
27.
Broex EC, van Asselt AD, Bruggeman CA, van Tiel FH: Surgical site infections: how high are the costs? J Hosp Infect 2009;72:193-201.
28.
Kim SP, Shah ND, Karnes RJ, Weight CJ, Frank I, Moriarty JP, Han LC, Borah B, Tollefson MK, Boorjian SA: The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. J Urol 2012;187:2011-2017.
29.
Zhan C, Miller MR: Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA 2003;290:1868-1874.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.